Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide that was being developed for inflammatory bowel diseases (IBD). ... Read more
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 read more
Protagonist Therapeutics Reports Granting of Inducement Award read more
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 read more
There are currently no events scheduled.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|